- Conditions
- Measles, Mumps, Rubella, Varicella
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 16 Months
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 73
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Herpes Zoster, Herpes Zoster Vaccine
- Interventions
- Herpes Zoster vaccine (GSK 1437173A)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 651 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Mesa, Arizona • Wichita, Kansas • Milford, Massachusetts
- Conditions
- Herpes Zoster
- Interventions
- Herpes zoster vaccine (GSK 1437173A), Placebo
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 568 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 8
- States / cities
- Inverness, Florida • Chicago, Illinois • Elkhart, Indiana + 5 more
- Conditions
- Chickenpox
- Interventions
- Investigational varicella vaccine, Marketed varicella vaccine, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 750 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Huntington Park, California + 18 more
- Conditions
- Meningococcal Infections
- Interventions
- MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 7 Months to 1 Year
- Enrollment
- 1,630 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Greenville, Alabama + 69 more
- Conditions
- Tetanus, Diphtheria, Pertussis, Measles, Polio
- Interventions
- Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus, Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 3,372 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Pinson, Alabama • Trussville, Alabama + 60 more
- Conditions
- Hepatitis C
- Interventions
- Zoster vaccine live
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 50 Years to 60 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chickenpox
- Interventions
- Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency, Licensed varicella vaccine Lot 1, Licensed varicella vaccine Lot 2, Measles, mumps, and rubella vaccine, Hepatitis A vaccine, 13-valent pneumococcal conjugate vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 41
- States / cities
- Bryant, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 37 more
- Conditions
- Persistence of Varicella Immunity
- Interventions
- Varicella vaccine
- Biological
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Haemophilus Influenzae Type b, Neisseria Meningitidis
- Interventions
- GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014), PedvaxHIB, Prevnar, M-M-R II, Varivax
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 4,021 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 45 more
- Conditions
- Chickenpox
- Interventions
- Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3, Marketed varicella vaccine_Lot 1, Marketed varicella vaccine_Lot 2, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 15 Months
- Enrollment
- 1,840 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 59
- States / cities
- Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
- Interventions
- Shingrix vaccine
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Chickenpox, Rubella, Rubeola, Mumps
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 12 Months to 16 Months
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Kidney Transplant Recipients
- Interventions
- Varivax®
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2001
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
- Conditions
- Common Variable Immune Deficiency, Specific Antibody Deficiency, X-linked Agammaglobulinemia
- Interventions
- Zostavax®
- Biological
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Measles, Mumps, Rubella, Varicella (Chickenpox), Measles-Mumps-Rubella+Chickenpox Vaccine
- Interventions
- MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 4 Years to 6 Years
- Enrollment
- 1,860 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 38
- States / cities
- Jonesboro, Arkansas • Little Rock, Arkansas • Huntington Park, California + 32 more
- Conditions
- Hepatitis A
- Interventions
- Havrix®, M-M-R®II, VARIVAX®
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Months to 13 Months
- Enrollment
- 1,474 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2009
- U.S. locations
- 42
- States / cities
- Cabot, Arkansas • Jonesboro, Arkansas • North Little Rock, Arkansas + 37 more
- Conditions
- HIV Infections
- Interventions
- Varicella Virus Vaccine (Live)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Months to 8 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2005
- U.S. locations
- 25
- States / cities
- Long Beach, California • Los Angeles, California • Oakland, California + 16 more
- Conditions
- Herpes Zoster, HIV Infections
- Interventions
- ZOSTAVAX, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric
- Interventions
- Observational only: Serology and flow cytometry for ALL cohort participants, Observational only: Infection rates
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 3 Years to 31 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Grand Rapids, Michigan • Philadelphia, Pennsylvania + 3 more
- Conditions
- Measles, Mumps, Rubella, Varicella
- Interventions
- MMR-II, Pro-Quad, Varivax
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Months to 12 Months
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Immunosenescence, Shingles
- Interventions
- Varicella Zoster Virus Vaccine (Zostavax)
- Biological
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Herpes Zoster
- Interventions
- HZ/su, Flu D-QIV, mRNA-1273
- Biological · Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,013 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 46
- States / cities
- Tempe, Arizona • Oxnard, California • San Diego, California + 40 more
- Conditions
- Fever After Vaccination, Fever, Seizures Fever
- Interventions
- mRNA COVID-19 Vaccine, Routine Childhood Vaccinations
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 6 Months to 4 Years
- Enrollment
- 347 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 5
- States / cities
- Oakland, California • Atlanta, Georgia • New York, New York + 2 more